Find Ophthalmology Drugs in Phase III Clinical Development in UNITED STATES

Lead Product(s): Bevacizumab

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: BioLexis Pte. Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 28, 2020

Details:

Outlook Therapeutics signed agreement with BioLexis Pte. Ltd to better align the interests of all parties with common stockholders of the Company and to help ONS-5010's continuing development.

Lead Product(s): Reproxalap

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

The INVIGORATE Trial, which will enroll approximately 120 patients aims to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared with vehicle using an allergen chamber.

Lead Product(s): Loteprednol Etabonate

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 15, 2020

Details:

If approved, Kala plans to commercialize KPI-121 0.25% under the brand name EYSUVISâ„¢.

Lead Product(s): Emixustat Hydrochloride

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

This publication supports the rationale for investigating emixustat in the treatment of Stargardt disease and diabetic retinopathy.